nafamostat has been researched along with Retinal Degeneration in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Retinal Degeneration: A retrogressive pathological change in the retina, focal or generalized, caused by genetic defects, inflammation, trauma, vascular disease, or aging. Degeneration affecting predominantly the macula lutea of the retina is MACULAR DEGENERATION. (Newell, Ophthalmology: Principles and Concepts, 7th ed, p304)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fuwa, M | 1 |
| Kageyama, M | 1 |
| Ohashi, K | 1 |
| Sasaoka, M | 1 |
| Sato, R | 1 |
| Tanaka, M | 1 |
| Tashiro, K | 1 |
1 other study available for nafamostat and Retinal Degeneration
| Article | Year |
|---|---|
Nafamostat and sepimostat identified as novel neuroprotective agents via NR2B N-methyl-D-aspartate receptor antagonism using a rat retinal excitotoxicity model.
Topics: Animals; Benzamidines; Cell Death; Cerebral Cortex; Excitatory Amino Acid Antagonists; Guanidines; I | 2019 |